News

Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma

Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.

News

LGBTQIAS2+ Cancer Symposium

Register Now! Patient-Centered Approaches in Cancer Prevention and Care Saturday, November 2, 2024 8:30 a.m.-2 p.m.

News

Inherited Changes in BRCA Genes Linked to Increased Risk of Multiple Myeloma

While multiple myeloma affects mostly older adults — 95% are over 50 Kenan Onel, MD, and his colleagues discovered that patients whose BRCA genes contained PGVs, which dramatically increase cancer risk, were more likely to be diagnosed ...

News

Congressman Kennedy Announces Over $7.7 Million for State-of-the-Art Biobank at Roswell Park

Congressman Kennedy announced $7,731,872 in funding for the Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National ...

News

Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia

The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).

News

Clinical Trial Evaluates Promising Immunotherapy Combination For Metastatic Triple Negative Breast Cancer

Encouraging results from a phase 1 clinical trial conducted at Roswell Park Comprehensive Cancer Center between 2019-2020 have laid the foundation for a phase 1/2a study for patients with metastatic or unresectable triple negative breast cancer (mTNBC)